

VITEK[®] REVEAL[™]

GRAM NEGATIVE BC PANEL (GN02-AST)



- ✓ Antimicrobial susceptibility test (AST) results as early as 3 hours directly from positive blood culture.¹
- ✓ Wide antimicrobial coverage for gram-negative bloodstream infections, with 12 organisms and 16 drugs.

ANTIMICROBIAL DRUG	MIC CALLING RANGE (µg/ml)	Organisms											
		<i>A. baumannii-calcoaceticus</i> complex	<i>C. freundii</i> complex	<i>C. koseri</i>	<i>E. cloacae</i> complex	<i>E. coli</i>	<i>K. aerogenes</i>	<i>K. oxytoca</i>	<i>K. pneumoniae</i> group	<i>P. mirabilis</i>	<i>P. vulgaris</i>	<i>P. aeruginosa</i>	<i>S. marcescens</i>
Amoxicillin / Clavulanate	4/2 - 16/8					✓		✓	✓	✓			
Ampicillin / Sulbactam	2/1 - 64/32					✓		✓		✓			
Cefepime	0.5 - 32			✓	✓	✓	✓	✓	✓			✓	
Ceftazidime	0.12 - 32	✓		✓	✓	✓	✓	✓	✓			✓	
Ceftazidime / Avibactam	0.06/4 - 16/4		✓	✓	✓	✓	✓		✓	✓		✓	
Ceftolozane / Tazobactam	0.12/4 - 32/4			✓	✓	✓	✓	✓		✓	✓	✓	
Ceftriaxone	0.25 - 16				✓	✓	✓	✓	✓	✓			
Ciprofloxacin	0.25 - 2		✓		✓	✓	✓	✓	✓		✓	✓	✓
Ertapenem	0.12 - 1					✓			✓	✓	✓		
Imipenem	0.5 - 8	✓		✓	✓	✓		✓	✓			✓	✓
Levofloxacin	0.12 - 4		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Meropenem	0.5 - 16	✓			✓	✓			✓	✓	✓	✓	✓
Meropenem / Vaborbactam	1/8 - 16/8		✓	✓	✓	✓	✓	✓	✓	✓			
Piperacillin / Tazobactam	2/4 - 64/4			✓		✓			✓		✓		
Tobramycin	0.5 - 8		✓	✓	✓	✓	✓	✓	✓	✓		✓	✓
Trimethoprim / Sulfamethoxazole	2/38 - 4/76					✓	✓		✓				




System reports results with S/I/R interpretation according to FDA Susceptibility Test Interpretive Criteria (STIC)

NOVEL TECHNOLOGY DETERMINES MIC* DIRECTLY FROM POSITIVE BLOOD CULTURE

**OPTIMIZE DIAGNOSTICS.
OPTIMIZE THERAPY.**
With our complete solution
for antimicrobial stewardship.

The panel includes highly sensitive nanoporous sensors. The sensors change color in response to metabolic volatiles produced by microorganisms during growth to quantify antibiotic efficacy.

*minimum inhibitory concentration



Panel Information

Breakpoint Standards: CLSI / FDA STIC

VITEK REVEAL BC GN02-AST PANEL: 424883

References

1. BMX.1129899 Clinical Trial Summary Report (proprietary, on file at bioMérieux).
2. Rottman M *et al.* Clinical evaluation of the VITEK® REVEAL™ (previously branded SPECIFIC REVEAL) Rapid AST System with Gram-negative bacteremia samples in 6 hospitals in France and England. Poster presented at: ECCMID; 2022 May; Lisbon, Portugal.



bioMérieux, Inc. • 515 S Colorow Drive • Salt Lake City, UT 84108 • USA • Tel: (800) 682 2666 • Fax: (800) 968 9494
www.biomerieux-usa.com • @bioMerieuxUSA